Introduction
in contrast to the predominantly pediatric forms of arthritis such as oligoarticular, polyarticular (rheuma toid factor [rF]negative) and systemic juvenile idiopathic arthritis (Jia), most patients with spondylo arthritis (spa) begin experiencing symptoms in the third and fourth decades of life. nevertheless, disease onset extends well into the pediatric age range, and juvenile spa represents an important form of arthritis in children that needs to be recognized, appropriately managed, and followed carefully for signs and symptoms of progression. enthesitisrelated arthritis (era) is a subtype of Jia as defined by the international league of associations for rheumatology (ilar) classification system for childhood arthritis.
1 era includes certain forms of spa, distinguish ing them from other subtypes of Jia for optimum treatment and outcome, and for studies aimed at understanding genetic predisposition and patho genesis. the inclusion and exclusion criteria for era recognize pheno typic and genetic differences between this and other forms of childhood arthritis, as well as differences in the presentation of spa between children and adults.
the ilar criteria for Jia generally perform well compared with previous systems for classifying juve nile arthritis ('juvenile rheumatoid arthritis or Jra' by american College of rheumatology criteria, and 'juvenile chronic arthritis or JCa' by european league against rheumatism criteria), [2] [3] [4] but their application to cases of juvenile spa has been more controversial. 5 although revisions to the ilar criteria have addressed some weaknesses, 1, [6] [7] [8] several problems remain, some of which might have been intensified by the recent develop ment of criteria that identify preradiographic 'axial spa' in adults. 9, 10 this review summarizes the clinical features, genetic susceptibility factors and outcomes of era, and discusses some of the implications of using the current ilarbased Jia classification system for juvenile spa in the context of how this disease is classified in adults.
Spondyloarthritis the spondyloarthropathies encompass a group of inflam matory arthritic diseases that exhibit overlapping clinical features and shared genetic predisposition (Box 1). the prototype spondyloarthropathy, ankylosing spondyli tis (as), is defined by criteria that require axial disease documented as radiographic sacroiliitis, 11 and by clinical signs and symptoms that reflect the involvement of addi tional joints in and around the spine. 12 Common mani festations of as that vary in frequency include peripheral arthritis, peripheral enthesitis, acute anterior uveitis and subclinical gastrointestinal inflammation (Box 2). the axial inflammatory lesions associated with as have a ten dency to ossify, resulting in ankylosis and contributing to a reduced quality of life and, in many patients with as, substantial disability.
Historically, the classification of SpA has been handled differently in adults ■ and children
Using the ILAR system, most juvenile SpA will be classified as enthesitis-related ■ arthritis or undifferentiated arthritis, depending on whether psoriasis is present in the patient or their family
The ILAR system does not specifically address children who have SpA by ■ fulfilling the criteria for ankylosing spondylitis, or who have coexisting conditions such as inflammatory bowel disease
The development and validation of criteria that recognize juvenile SpA with ■ axial inflammation could be an important step in facilitating therapeutic trials in children HLA-B27 is only one element of the complex genetics of ankylosing spondylitis, ■ and additional susceptibility genes could be useful predictors of long-term outcome in children with early, undifferentiated SpA many individuals with signs and symptoms of spa do not meet the criteria for as because they either lack axial involvement or do not show radiographic evidence of sacroiliitis. instead, such patients often meet classifi cation criteria for 'undifferentiated spa' , as defined by european spondyloarthropathy study Group (essG) 13 or amor criteria 14 (Box 1). the criteria for undifferen tiated disease overlap with those for other forms of spa, includ ing reactive arthritis, and for arthritis accompany ing inflammatory bowel disease (iBD) or psoriasis. outcome studies reveal that undifferentiated spa is not merely an early form of as since, even after a decade, almost half of patients still do not meet criteria for as. 15 striking advances in the treatment of as have been realized over the past decade. several biologic agents that target tumor necrosis factor (tnF) have been shown to be rapidly beneficial in a high proportion of patients with as, with substantial reductions in pain, inflammation, and disease activity. 16 However, it seems that tnF inhibi tion might not modify the radiographic progression of spinal disease, at least in patients whose treatment was initiated after they fulfilled criteria for as. 17, 18 these observations, along with the prospect of new biologic agents, have intensified interest in identifying early (pre radiographic) axial disease, which might be more amen able to disease modification than latestage disease. since the criteria for undifferen tiated spa do not specifically identify indivi duals with axial disease, the development by the assessment of spondyloarthritis international society (asas) of new criteria for this purpose is both noteworthy and timely ( Figure 1) . 9, 10 this achievement is in large part attributable to the use of mri to identify early, preradiographic axial lesions (for example, see Figure 2 ), although the usefulness of HlaB27 testing is also recognized. application of the asas criteria reveals that they identify both radiographic spa (that is, indivi duals who meet the modified new York criteria for as) and pre radiographic axial spa. this major advance will facilitate the identification of patients who are appro priate for early intervention, and will enable further dis covery and validation of biomarkers associated with axial involvement. 19 Juvenile spondyloarthritis recognizing spa in children, particularly early in the course of disease, presents a unique set of challenges. the signs and symptoms at disease onset differ from those seen in adults, with inflammatory back pain being less prominent, reflecting the infrequent involvement of the sacroiliac and other vertebral joints in juvenile disease. 20 By contrast, hip and peripheral arthritis, together with enthesitis, are common presenting features in children. as a consequence, juvenile spa might be missed or confused with other forms of juvenile arthri tis. in recognition of these differences, rosenberg and Petty proposed criteria for a syndrome of seronegative enthesopathy and arthropathy (sea), including the pres ence of enthesitis with arthralgia or arthritis, the absence of rF and antinuclear antibodies, and symptom onset before 17 years of age. 21 sea provided a category that revIews recognized undifferentiated juvenile spa in the absence of axial symptoms, and thus became a useful means to distinguish this syndrome from Jra as it was defined at the time (1980s) by aCr criteria. in the mid1990s, the ilar classification criteria were proposed, using the umbrella term Jia. 6, 7 the primary intent of these criteria was "to delineate, for research purposes, relatively homogeneous, mutually exclusive categories of idiopathic childhood arthritis based on pre dominant clinical and laboratory features".
1 six categories of Jia were proposed, with a seventh (originally called "undefined arthritis", now referred to as "undifferen tiated arthritis") applied if the criteria for other catego ries were either not met or did not enable unambiguous classification. the practical application of these criteria, however, identified a large number of children as having 'undefined arthritis' , 22, 23 prompting revision and further clarification of the categories (table 1) . 1 under the revised ilar classification system published in 2004 (table 1) , juvenile spa is largely categorized in one of three ways: as era, psoriatic arthritis (Psa), or undifferentiated arthritis (if features of both era and Psa are present). the definition of era is based on cri teria similar to those of sea, but applied differently and with some important distinctions. Coexisting arthritis and enthesitis are sufficient for the classification of era, provided other exclusions are absent. if the patient does not have both arthritis and enthesitis, then additional features suggestive of spa must be present (table 1) . By contrast, enthesitis without arthritis would be sufficient for the classification of sea. other major differences include an upper age limit of 16 for era rather than 17 for sea, and how psoriasis influences the classifica tion. in the ilar system, the presence of psoriasis in the patient or a firstdegree relative is an exclusion criterion for era and all other subgroups of Jia except Psa. a classification of Psa is considered if the patient has both arthritis and psoriasis, or has arthritis plus at least two of dactylitis, characteristic nail changes and a firstdegree relative with psoriasis (table 1) .
one could argue that Psa, as defined by the ilar cri teria, is not spa. recent studies suggest that ilar defined psoriatic and nonpsoriatic Jia can have similar clinical features, with the main differences being an increased frequency of dactylitis and nail pitting (in addition to the presence of psoriasis) in Psa. 24, 25 one study revealed small differences in outcomes, with juve nile Psa resulting in poorer physical health and more pain than oligo articular or polyarticular Jia, 25 and axial involvement was either absent 25 or not specifically noted in psoriatic Jia. 24 By contrast, application of the vancouver criteria for juvenile Psa, 26 which predate the ilar classification and are more inclusive, 1,7 reveals two distinct populations of patients: a young group (age at onset <5 years) with a disease that resembles Jia 27 and is similar to ilardefined Psa, and an older group (age at onset ≥5 years) with a tendency to have enthesi tis, axial arthritis and persistent oligo arthritis. Patients in the latter group are often excluded from a classifica tion of ilardefined Psa (for example, because they are male and HlaB27 positive, and/or have features of, or a family history of, spa), and are instead classified as having undifferentiated arthritis (table 1) . 28 the question 
Inflammatory bowel disease
Crohn disease or ulcerative colitis ■ Asymptomatic inflammation in the terminal ileum and ■ colon has also been found in a large proportion of patients with ankylosing spondylitis
Nail pitting
A minimum of two pits on one or more nails at any time ■
Psoriasis
Chronic skin inflammation usually associated with thick ■ red patches with flaky silver-white scales Figure 1 | ASAS classification criteria for axial spondyloarthritis. 9,10 'Sacroiliitis on imaging' is defined as active (acute) inflammation on MRI highly suggestive of sacroiliitis associated with SpA (see Figure 2 ), or as 'definite radiographic sacroiliitis' according to the modified New York criteria. 12 'Features of SpA' include inflammatory back pain, arthritis, enthesitis (heel), uveitis, dactylitis, psoriasis, Crohn disease or ulcerative colitis, good response to treatment with NSAIDs, positive family history of SpA, HLA-B27, and elevated CRP level (considered a feature of SpA in the context of chronic back pain). The entire criteria have a sensitivity 82.9% and specificity 84.4%, as tested in 649 patients with chronic back pain and age at onset <45 years, and the imaging (sacroiliitis) arm alone has a sensitivity of 66.2% and a specificity of 97.3%. 9, 10 Abbreviations: ASAS, Assessment of SpondyloArthritis International Society; CRP, C-reactive protein; SpA, spondyloarthritis. revIews of how to best define Psa in children, and in particular whether one should subdivide oligoarticular Jia and polyarticular Jia according to the presence or absence of psoriasis in the patient or their family, is an area of active debate. 29 this issue extends to juvenile spa, where the question is whether children with era who also have features of psoriasis or a family history of disease should be excluded from a classification of era.
the era classification criteria do not address reactive arthritis or coexisting iBD, 30 which are considered features of spa in adults. a diagnosis of iBD does not exclude a patient from having era, as long as the inclusion criteria are met. nevertheless, one consequence of not recogniz ing iBD as a possible feature of spa is that a 15yearold male with iBD and arthritis, but not enthesitis, HlaB27, or a family history of spa, would not be con sidered to have spa until he turned 16 years old, unless the cri teria for undifferentiated spa in adults (essG criteria 13 or amor criteria 14 ) were to be applied before that time. in addition, the criteria for era actually contradict those for Jia, since arthritis does not have to be present for a classi fication of era. the correct approach to the classification of era is uncertain, and this issue is clearly confusing to both pediatric and adult rheumatologists.
the ilar classification system for Jia, and the era subgroup in particular, does not specifically address chil dren who meet the criteria for as. approximately 10% to 20% of patients eventually diagnosed with as begin to experience symptoms before the age of 16, 31 and a pro portion of these individuals would fulfill the modified new York criteria for as at this early age. the criteria for as do not specify a lower age limit, and when children fulfill these criteria it is logical to classify them as having as, even if they also meet the criteria for era. the term 'juvenile as' , then, could be used to describe children who meet the criteria for as before age 16, whereas ' juvenileonset as' would describe those whose symp toms began before age 16 but who do not fulfill the as criteria until they are older.
Prevalence estimates of the prevalence of juvenile spa, and era speci fically, are based on figures for juvenile arthritis, which vary considerably depending on geographic location and case definition. the worldwide prevalence of juvenile arthritis is reportedly between 7 and 400 per 100,000 chil dren (0.007% to 0.4%), although the latter figure seems to be an outlier and probably over estimates the number of cases in the usa. 32 era and Psa each comprise 2-11% of those cases, 33 which would give an estimated combined total of 0.28-88 cases per 100,000 children. these figures do not seem to include juvenile as, which, based on the prevalence of as in adults and the frequency of childhood onset among as patients, is prevalent in 0.01% to 0.09% of the pediatric population. 31, 33 treatment there is virtually no published evidence for the treatment of era. 34 sulfasalazine might be beneficial for peripheral arthritis in this subgroup of Jia patients, although this benefit is not well established. 35 tnF inhibitors have shown promise in a small openlabel trial of juvenile spa patients who met the ilar criteria for era and the essG criteria for spa, 36 and, given their benefit in as, their efficacy in reducing symptoms and inflammation is not surprising. nsaiDs are frequently used to manage symptoms in most forms of inflammatory arthritis, including spa, and could be of benefit in reducing radiographic progression in as if used con tinually. 37 education, exercise, and physical and occupational therapy for stretching and maintaining range of motion are usually key components of management. 38 genetic susceptibility the majority of recent efforts to understand genetic suscepti bility to spa using genomewide approaches have focused on as. this is a complex genetic disease, and evi dence indicates that over 90% of the risk of developing the disease is heritable, suggesting that environmental influ ences, although potentially important, are most likely ubiquitous. 39 Genetic susceptibility to as is dominated by one family of mHC class i alleles, HlaB27, which accounts for close to 40% of heritability. 40 it is almost necessary for disease (present in more than 90% of as patients compared with 7-8% of healthy controls), but is clearly not sufficient, as only around 5% of HlaB27 carriers develop as.
looking beyond the mHC, ERAP1 (formerly known as ARTS1) and IL23R have been associated with as, with populationattributable risk estimates of 26% and 9%, respectively. 41, 42 the first genomewide association study of as confirmed the associations of ERAP1 and IL23R, and identified ANTXR2 and IL1R2 as additional revIews susceptibility genes. 43 associations with singlenucleotide polymorphisms in gene deserts (2p15 and 21q22) 43 and in or near TNFR1, CARD9 and TRADD, suggest that additional candidate genes or gene regions are still to be confirmed. together, these genes could account for nearly 70% of genetic susceptibility to as, with other genes such as IL1A also implicated. 40 it is worth noting that IL23R polymorphisms, which are also implicated in psoriasis and iBD, 44, 45 are independently associated with as. this observation could explain, at least in part, the coexistence , presence of HLA-B27 antigen, onset of arthritis in a male over 6 years of age, acute (symptomatic) anterior uveitis, history of AS, eRA, sacroiliitis with IBD, reactive arthritis, or acute anterior uveitis in a first-degree relative Psoriasis or a history of psoriasis in the patient or a first-degree relative Presence of IgM RF on at least two occasions at least 3 months apart Systemic JIA in the patient
Undifferentiated arthritis
Arthritis that fulfills criteria in none of the above categories, or fulfills criteria in two or more of the above categories NA *JIA is arthritis of unknown etiology that begins before the patient's sixteenth birthday and persists for at least 6 weeks. ‡ Inflammatory lumbosacral pain is defined as lumbosacral pain at rest with morning stiffness that improves with movement. Abbreviations: AS, ankylosing spondylitis; eRA, enthesitis-related arthritis; IBD, inflammatory bowel disease; ILAR, International League of Associations for Rheumatology; JIA, juvenile idiopathic arthritis; NA, not applicable; RF, rheumatoid factor. revIews of and phenotypic overlap between various forms of spa, and underscores the difficulty in defining nonoverlapping subtypes of disease for the purposes of classification.
the role of newly discovered as risk genes in era and other forms of undifferentiated spa has not been investi gated. HlaB27 is strongly associated with juvenile spa, being found in 60% to 90% of affected indivi duals depend ing on the type of spa.
46-48 the strength of the association between HlaB27 and era cannot be assessed since the presence of HlaB27 antigen is used as a minor inclu sion criterion for the classification of era (table 1). since risk alleles for genes such as IL23R and ERAP1 were dis covered in the context of as, and only a proportion of era patients will develop the complete as phenotype, the frequency of as risk alleles in patients with era could be closer to that seen in healthy indivi duals than in patients with as. whether there are independent risk alleles for era remains to be determined. it seems probable that the presence of as risk alleles in individuals with era (or with other forms of undifferen tiated spa) could predict progression to axial involvement and eventual ankylosis. longterm outcome studies of era will be important if predictive genetic tests are to be developed.
Pathogenesis an indepth discussion of the pathogenesis of spa is beyond the scope of this review, and has been covered recently elsewhere. 49, 50 However, a few developments are worth noting. the predominant place of HlaB27 in determining genetic predisposition to spa has shaped many ideas about the pathogenic mechanisms of the disease, and a transgenic animal model has enabled some of these hypotheses to be tested. 50 in HlaB27 trans genic rats with spalike disease, the lack of a critical role for CD8 + t cells has been confirmed. 51, 52 this finding essentially eliminates a causative role for the recognition of arthritogenic peptides by autoreactive CD8 + t cells, although skeptics would argue that the rat model does not adequately represent human as.
interest is growing in the intracellular effects of HlaB27 expression. HlaB27 misfolding, and the ensuing unfolded protein response induced by endo plasmic reticulum stress, results in increased il23 production in response to patternrecognition recep tor agonists; il23 might then activate existing il17 expressing CD4 + t cells (type 17 t helper [t H 17] cells). 49, 50, 53, 54 t H 17 cyto kines, either alone or in combina tion with t H 1 cytokines, have been implicated in a variety of pathogenic processes in animals and humans. 55 strong evidence in support of this concept comes from studies of colitis lesions in HlaB27 transgenic rats, but data from human studies are needed and links to other aspects of the as phenotype have not been addressed. in addition, this mechanism could explain why IL23R polymorphisms are linked to a predominantly mHC class i (HlaB27) associated disease and to t H 17 cell activation, findings that have now been documented in humans with as and other forms of spa. [56] [57] [58] [59] one function of the enzyme encoded by ERAP1, an endoplasmic reticulum aminopeptidase, is to trim and optimize peptides that are presented by mHC class i mol ecules. [60] [61] [62] thus, ERAP1 polymorphisms might logically be expected to influence the immunobiology of HlaB27 through its peptide repertoire, including putative arthrito genic or spondylogenic peptides. 50 if the results from transgenic rats are correct and peptides per se are not critical for disease, then another effect on HlaB27 could be involved, such as alterations to its folding-misfolding dynamics in the endoplasmic reticulum or its behavior after reaching the cell surface. these possibilities need to be addressed experimentally. Possible functional inter actions between the products of genes associated with as are displayed in Figure 3 . outcome the reported longterm prognosis for patients with juve nile spa is variable, and depends on which study one examines. this inconsistency is probably a consequence of several factors, including the use of different case defi nitions for juvenile spa, but also depends on the popula tion being studied. the original report of sea described 39 children, 13 of whom had classical features of spa including 8 with bilateral sacroiliitis, 2 with iBD, and 3 with reactive arthritis. 21 thirtysix of the 39 were followed for a mean of 11 years, and were found to have a variable disease course. 63 Half of the original group who did not have definite spa at onset (but who fit the criteria for sea) eventually developed definite or possible spa. the presence of HlaB27, arthritis rather than arthralgia, and disease onset after age 5 years predicted eventual spa.
in comparison with other forms of juvenile arthritis, juvenile spa tends to have a poorer outcome. in one 3year study, patients with either juvenile as or sea had poorer health outcomes than patients with oligo articular Jra and rF polyarticular Jra, and similar outcomes to those with rF + polyarticular Jra, with a high dis ability index and poor wellbeing at baseline being the best predictors of poor outcomes. 64 in the largest study to date, similar findings of worse physical outcomes were observed for era compared with oligoarticular or poly articular Jia after a median of 15.3 years and also after a median of 23.0 years. 65 at 15.3 years, 44% (24/55) of patients with era were in remission while 56% (31/55) had reduced anterior spinal flexion. radiographic sacroili itis was present in 35% (19/55) and inflammatory back pain in 47% (26/55). Predictors of failure to achieve remission included genetic components, as measured by a positive family history of as in a firstdegree relative and the presence of HLA-DRB1*08 in the patient, and clinical features of ankle or hip arthritis within the first 6 months of disease. Predictors of sacroiliitis included persistently elevated erythrocyte sedimentation rate and ankle arthritis. HlaB27 was not a predictor of poor outcome in this study, perhaps because it was present in the vast ma jority of patients (85%). these data suggest that, even after 15 years, less than half of patients classi fied as having era have evidence of active spinal disease, a key feature of as. this pattern differs slightly from that of undifferentiated spa in adults classi fied according to essG criteria. one study demonstrated revIews that undifferentiated spa progressed to as in 60% of patients after an average of 10 years of followup. 15 the sometimes slow but persistent progression of this disease underscores the need for better bi omarkers including genetic predictors of outcome.
the value of testing for the presence of HlaB27 antigen has historically been a matter of debate, since it neither rules in nor excludes a diagnosis of juvenile as. However, its use as a minor inclusion criterion for era, and as an exclusion criterion (along with age and sex) for other forms of Jia, argues that it should be rou tinely ascertained when using the ilar classification system. in support of the usefulness of this test, HlaB27 predicts increasingly extended disease within the first 3 years with increasing age at onset in boys with Jia. 66 it is also associated with involvement of small joints in the lower extremities (primarly subtalar and tarsal joints) in boys but not in girls, and with inflammatory back pain in both sexes.
age at onset appears to influence outcomes for patients with as. in one study, patients with disease onset before age 16 years tended to have moresevere hip disease, as reflected by a greater need for arthroplasty (17.7% versus 8.7% for patients with juvenileonset and adultonset as, respectively) and radiographic changes, while patients with adultonset disease exhibited worse spinal radio graphic scores. 67 another study demonstrated adult onset as to have moreprominent axial features such as pain and stiffness in the neck and back, with worse functional outcome, quality of life and fatigue. 68 Disease duration was similar between the two groups, although disease activity was higher in patients with as onset during adulthood. this study also confirmed differ ences in presentation of spa between adults and chil dren, with 26% of patients with juvenileonset as having only peripheral arthritis at onset, compared with 4.6% of patients with adultonset disease.
Conclusions
the ilar system for classifying Jia has been adopted worldwide, and represents an improvement over pre vious classification systems. 8 ideally, classification cri teria for juvenile spa should be both sensitive and specific, recognizing differences in the presentation of spa in childhood as opposed to adulthood, but should also be sufficiently similar to adult criteria to include CARD9 mediates IL-23 induction in response to fungal cell wall components through the PRR, Dectin-1. eRAP1 influences the quality and/or quantity of peptides available for MHC class I molecules, and might impact not only cell-surface complexes, but also the folding efficiency of HLA-B27. eRAP1 (also known as ARTS1) is also an aminopeptidase regulator of TNF (TNFR1) receptor shedding, and also influences IL-6 and IL-1R2 (IL1R2) receptors. Polymorphisms in TNFR1 and TRADD, a mediator of TNF signaling, could influence downstream effects perhaps contributing to phenotypic differences between patients with different TNF overexpression diseases such as RA and AS. Abbreviations: AS, ankylosing spondylitis; BiP, immunoglobulin-heavy-chain-binding protein; CARD9, caspase recruitment domain-containing protein 9; eR, endoplasmic reticulum; eRAP1, endoplasmic reticulum aminopeptidase 1; IFN, interferon; IL, interleukin; NK, natural killer; PRR, pattern recognition receptor; RA, rheumatoid arthritis; T H 17, type 17 helper T cell; TNF, tumor necrosis factor; TNFR1, tumor necrosis factor receptor type 1; TRADD, TNFR1-associated DeATH domain protein; UPR, unfolded protein response; XBP1, X-box-binding protein 1.
revIews conditions that fall under the spa umbrella such as juve nile as and 'juvenile' axial spa. this would facilitate communication between adult and pediatric physicians and rheumatologists, and would be particularly impor tant for patients who are at the age to begin their transi tion into adult care. this consistency is also important for investigators in the field. the recent development of criteria that identify patients with axial spa before the appearance of radiographic changes or the fulfillment of criteria for as 9, 10 represents an important advance that will facilitate therapeutic trials to test whether early treatment with tnF inhibitors could change the course of axial disease.
revIews
